229 related articles for article (PubMed ID: 36484278)
1. Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
[TBL] [Abstract][Full Text] [Related]
2. Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
Tymon-Rosario J; Zeybek B; Santin AD
Curr Opin Obstet Gynecol; 2021 Feb; 33(1):26-33. PubMed ID: 32618744
[TBL] [Abstract][Full Text] [Related]
3. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Tolcher A; Hamilton E; Coleman RL
Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates in Gynecologic Cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract][Full Text] [Related]
5. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates in Gynecologic Cancer.
Karpel HC; Powell SS; Pothuri B
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
[TBL] [Abstract][Full Text] [Related]
8. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates in gynecologic malignancies.
Lee EK; Liu JF
Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates for the treatment of ovarian cancer.
Calo CA; O'Malley DM
Expert Opin Biol Ther; 2021 Jul; 21(7):875-887. PubMed ID: 32463296
[TBL] [Abstract][Full Text] [Related]
11. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
12. Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
Nerone M; Grande MD; Sessa C; Colombo I
Explor Target Antitumor Ther; 2022; 3(2):149-171. PubMed ID: 36046840
[TBL] [Abstract][Full Text] [Related]
13. Progress in Gynecologic Cancers with Antibody Drug Conjugates.
O'Malley DM; Calo CA
Curr Oncol Rep; 2021 Jun; 23(8):89. PubMed ID: 34125311
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates for ovarian cancer: current clinical development.
Stewart D; Cristea M
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
[TBL] [Abstract][Full Text] [Related]
15. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.
Wang AJ; Gao Y; Shi YY; Dai MY; Cai HB
Front Pharmacol; 2022; 13():1093666. PubMed ID: 36618922
[TBL] [Abstract][Full Text] [Related]
16. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.
Porter RL; Matulonis UA
Expert Rev Anticancer Ther; 2023; 23(8):783-796. PubMed ID: 37458180
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L; Oaknin A; Matulonis UA; Mantia-Smaldone GM; Lim PC; Castro CM; Provencher D; Memarzadeh S; Method M; Wang J; Moore KN; O'Malley DM
Gynecol Oncol; 2023 Mar; 170():241-247. PubMed ID: 36736157
[TBL] [Abstract][Full Text] [Related]
18. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
[TBL] [Abstract][Full Text] [Related]
19. Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer.
Mauricio D; Harold J; Tymon-Rosario JR; Zeybek B; Santin AD
Expert Opin Biol Ther; 2021 Aug; 21(8):1087-1096. PubMed ID: 33356644
[No Abstract] [Full Text] [Related]
20. Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals.
McNamara B; Chang Y; Goreshnik A; Santin AD
Int J Womens Health; 2023; 15():1353-1365. PubMed ID: 37663226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
